“Four monkeys/sex/group were sacrificed after the 26-week dosing period and the remaining 2 monkeys/sex/group were sacrificed after a 12-week recovery period.”
✓ VerifiedFDA pharmacology/toxicology review, p. 46Source ↗
Pivotal GLP studies
GLP cynomolgus repeat-dose studies: IV for up to 6 months and SC for 3 months
“The toxicity profile of sarilumab was evaluated in a number of GLP compliant repeat-dose toxicology studies in Cynomolgus monkeys by the intravenous (IV) route of administration for up to 6 months in duration and by the SC route for 3 months duration.”
✓ VerifiedFDA pharmacology/toxicology review, p. 46Source ↗
Route in tox
Intravenous and subcutaneous
“Pivotal nonclinical studies of sarilumab were conducted in Cynomolgus monkeys by intravenous and SC dosing”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗